Erschienen in:
01.12.2015 | Orthopedic Oncology: New Concepts and Techniques (JH Schwab, Section Editor)
Rank ligand as a target in musculoskeletal neoplasms
verfasst von:
Gregory M. Cote
Erschienen in:
Current Reviews in Musculoskeletal Medicine
|
Ausgabe 4/2015
Einloggen, um Zugang zu erhalten
Abstract
Receptor activator of nuclear factor-κB ligand (RANKL) is a tumor necrosis factor (TNF) family member, which signals through the osteoclast surface RANK. As such, RANKL is required for osteoclast differentiation and function, namely bone resorption. There is now growing evidence that RANKL is a therapeutic target for musculoskeletal neoplasms, namely giant cell tumor of bone (GCTB) and osteosarcoma.